Decoding ANAB (AnaptysBio) through the lens of “development × partnerships × royalty assets”: the winning formula in immuno-biotech—and the less visible vulnerabilities
This is a comprehensive investment analysis note that assesses ANAB’s (ANAB) growth potential through the lens of structural changes in the AI era and clarifies the company’s relative fundamental positioning by comparing it with competitors, the market, and its own historical performance. It provides a systematic, all-angle framework covering everything investors need, including why the company appears poised to grow and what risks it faces.